Evolving paradigms in cardiovascular pharmacology: advances and clinical significance.

Cardiovascular disease is the leading cause of morbidity and mortality among both the elderly and the young, making cardiovascular drugs the most commonly prescribed medications for these populations. Cardiovascular conditions such as arrhythmias, coronary artery disease, hyperlipidemia, heart failure, and arterial hypertension are managed with these drugs. Over the past few decades, significant advances have been made in developing cardiovascular medications to prevent and treat various diseases. This review provides a comprehensive overview of recent advances in cardiovascular drug therapy, focusing on several key drugs and their pharmacokinetics and pharmacodynamics, including absorption, excretion, metabolism, and distribution. It highlights the mechanisms of action, routes of administration, side effects, and clinical implications of essential cardiovascular drugs, such as diuretics, angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, angiotensin II receptor blockers (ARBs), calcium channel blockers, and Digoxin. Additionally, the paper discusses the use of nanoscience and nanoparticles in the effective treatment of cardiovascular diseases, highlighting their role in reducing side effects and improving prognosis. Nanoparticles are gaining significant attention for the treatment of cardiovascular conditions due to their greater sensitivity and specificity. Reports indicate that nanotechnology or nanoscience can effectively treat over 50% of cardiovascular conditions.